TY  - JOUR
A1  - Schulmeyer, Carla E.
A1  - Fasching, Peter A.
A1  - Häberle, Lothar
A1  - Meyer, Julia
A1  - Schneider, Michael
A1  - Wachter, David
A1  - Ruebner, Matthias
A1  - Pöschke, Patrik
A1  - Beckmann, Matthias W.
A1  - Hartmann, Arndt
A1  - Erber, Ramona
A1  - Gass, Paul
T1  - Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis
JF  - Diagnostics
N2  - Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
KW  - early breast cancer
KW  - therapy
KW  - prognosis
KW  - CK5
KW  - CD117
KW  - EGFR
KW  - triple-negative breast cancer
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304987
SN  - 2075-4418
VL  - 13
IS  - 3
ER  - 
TY  - THES
A1  - Meyer, Julia
T1  - Klinische Relevanz der Bestimmung von MMP-9 und TIMP-1 in BALF bei Lungenfibrose- und Sarkoidosepatienten
T1  - Clinical relevance of the measurement of MMP-9 and TIMP-1   in BALF from patients with pulmonary fibrosis and sarcoidosis
N2  - Konzentrationen von MMP-9 und TIMP-1 (mittels ELISA) waren in der BALF von Lungenfibrosepatienten am höchsten, gefolgt von Sarkoidose- und Kontrollpersonen. Eine Beteiligung an der Entstehung einer Lungenfibrose konnte dementsprechend sowohl für MMP-9, als auch für TIMP-1 bestätigt werden. Dies ist vereinbar mit der Pathogenese der Erkrankung. MMP-9 degradiert Basalmembranen, ein Mechanismus, der für die Proliferation von Fibroblasten-Foci von Bedeutung ist. Die Konzentration von MMP und TIMP korrelierte positiv mit der Anzahl neutrophiler Granulozyten sowie Lymphozyten in der BAL und negativ zu Alveolarmakrophagen. Es stellte sich keine Beziehung zwischen MMP-9 bzw. TIMP-1 und dem klinischen Ausmaß der Erkrankung, gemessen an den Lungenfunktionswerten, heraus. Die molare Ratio von Patienten im Follow-up korrelierte jedoch signifikant negativ mit deren Vitalkapazität nach zwei Jahren. Aufgrund dieser Ergebnisse kamen wir zu der Schlussfolgerung, dass eine höhere Ratio mit einer Verschlechterung der Lungenfunktion im Verlauf einhergehen könnte.
N2  - Concentrations of MMP-9 and TIMP-1 (with ELISA) were highest in BALF of patients with pulmonary fibrosis, followed by patients with sarcoidosis and controlls. According to this, an involvement in the development of lung fibrosis could be confirmed for MMP and TIMP. This is compatible to the pathogenesis of the disease. MMP-9 degrades basalmembranes, a mechanism which is of importance for proliferation of fibroblast-foci. The concentration of MMP and TIMP correlated positively with the amount of neutrophil granulocytes and lymphocytes and negatively to alveolar macrophages. There was no correlation between MMP-9 respectively TIMP-1 and the clinical extent of the disease, measured by lung function. However, the molar ratio from patients in follow-up correlated significantly negatively with the vitalcapacity after two years. Because of these results we concluded that a higher ratio could go along with a decline in lung function.
KW  - Lungenfibrose
KW  - Sarkoidose
KW  - BALF
KW  - MMP
KW  - MMP-9
KW  - TIMP
KW  - TIMP-1
KW  - BALF
KW  - MMP
KW  - MMP-9
KW  - TIMP
KW  - TIMP-1
Y1  - 2009
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-40984
ER  -